4 ms·
Well the fact that drugs are twice as expensive (or more) in the US* and the fact that the US accounts for a huge chunk of government funding into the relevant
by jjoonathan 12y ago
Well the fact that drugs are twice as expensive (or more) in the US* and the fact that the US accounts for a huge chunk of government funding into the relevant sciences are part of the reason why drugs are so cheap overseas. British taxpayers buying drugs in Britain are effectively getting a subsidy from US taxpayers even though they don't pay into the pot, so this all seems like a stroke of cosmic justice where I'm standing. Of course, I doubt the British tax authorities care much about what I think.
* Why? Remember how bargaining works: the biggest customer gets the best deal. First imagine Kaiser, Wellpoint, and Aetna sitting down at the bargaining table. Now imagine Canada sitting down at the table. Now imagine the European Union sitting down at the table. But at least our insurance companies are more efficient due to competition, right? Spoiler: not even close, and that's before you take into account the costs they offload onto the rest of the system in the form of incompatible claims policies, paperwork, and exploitation of information asymmetry against consumers.
- giarc 12y agoI don't know figures, but I imagine Kaiser represents more than 35 million people (the approx population of Canada). Shouldn't they be able to negotiate the same price?
- refurb 12y agoBingo! The largest US private insurer (United) cover 40M lives in the US. They pay higher prices than nearly all European countries (even the ones with smaller populations). Drugs aren't cheaper in places like the UK because the gov't negotiates lower prices. Drugs are cheaper because the gov't mandates lower prices. People shouldn't confuse the two.
- zaroth 12y agoSo is the UK not concerned about mandating lower prices and squeezing the R&D funnel for new drugs... because Americans are making up the difference?
- adwf 12y agoDrug companies spend more on marketing drugs to doctors and consumers than they do on R&D. In the UK, marketing drugs is illegal and therefore they don't need to go to that expense. All they have to do is convince an NHS board and then it's on the list of approved prescribed drugs.
- maxerickson 12y agoDo you have a favorite citation for that factoid? Some similar claims I have looked at have used the "Selling, General, Administrative" off of an income statement as the marketing expense, but that category includes salaries and buildings and lots of other things, not just marketing expenses.
- adwf 12y agoJust a quick googling: http://www.washingtonpost.com/blogs/wonkblog/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research/ http://www.washingtonpost.com/blogs/wonkblog/wp/2015/02/11/b... http://www.bbc.co.uk/news/business-28212223 http://www.bbc.co.uk/news/business-28212223 Reading the BBC article reminded me of all the fines also. People are paying extra because drug companies push off-label uses on consumers and then get fined for it. It's not like the company really pays, they just up their prices a bit and push it onto the consumer. That sort of off-label usage doesn't happen in the UK so much, because doctors don't have any incentive to prescribe anything other than the NHS approved drug for a condition.
- maxerickson 12y agoSo here's the financial segment of Johnson and Johnson's 2013 annual report: http://2013annualreport.jnj.com/sites/2013annualreport.jnj.com/files/2013_Johnson_Johnson_Annual_Report_Audited_Consolidated_Financial_Statements.pdf http://2013annualreport.jnj.com/sites/2013annualreport.jnj.c... (linked from here: http://2013annualreport.jnj.com/financials http://2013annualreport.jnj.com/financials ) In one place, it says this: Advertising Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.5 billion, $2.3 billion and $2.6 billion in 2013, 2012 and 2011, respectively. That advertising number most likely does not include money they spend directly marketing to doctors and so on. So the Global Data report referenced by the BBC implies they are spending $15 billion directly marketing to doctors and other medical people/organizations. The next step would be to figure out what they are spending paying employees (with 120,000 of them, quite a lot), but I can't find good numbers on that.
- ptaipale 12y agoThe European Union is not bargaining as a single buyer. There are considerable differences between the health insurance systems of EU member countries, and each of them buys their medication differently. In fact, it looks to me that the US is closer to being a one buyer than the European Union, which would first need to do a lot of harmonizing and more or less set up a United States of Europe. Kaiser, Wellpoint and Aetna each have as many health plan members as a medium-sized European country. That's not the problem. As far as I understand, the problem is the unavailability of generic replacement medicines in the US, clearly for IPR reasons.
- geographomics 12y ago> Well the fact that drugs are twice as expensive (or more) in the US You have to compare like for like though - looking at the cost to the end user is not relevant, you'd have to look at the cost to the NHS versus the cost to US health insurance companies. For the NHS, this is publicly available data[1] and we can see that a course of once-daily apiprazole (the drug described in the article) costs the equivalent of $150-300 per patient per month, depending on formulation. Is such data (of actual cost) available for the US? Also, regarding biomedical research - the British taxpayer funds this as well. Anyway, apiprazole was developed in Japan. It's not all US-centric. [1] http://www.hscic.gov.uk/searchcatalogue?productid=14494 http://www.hscic.gov.uk/searchcatalogue?productid=14494